Circular of Shandong Province on Information Adjustment of Some Low-Price Drugs
According to the notification of Shandong Medical Security Bureau on adjusting the list of low-cost drugs, "Zhike Chuanbei Loquat Dropping Pills" adjusted the list of low-cost drugs withdrawn from our province, and "Fast Stomach Tablets" adjusted into the list of low-cost drugs in our province. Now the purchase type of "Zhike Chuanbei Loquat Dropping Pills" has been changed to "direct networking - small dosage drugs for clinical use", and the purchase type of "Quick Stomach Pills" has been changed to "direct networking - low-cost drugs", and the adjustment has been carried out according to the relevant rules.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-20
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
6th Drug Safety Symposium 2026 to Focus on “Beyond Algorithms & Assumptions, What Actually Matters in Pharmacovigilance”
-
Roche Acquires Carmot for $3.1 Billion to Enter Obesity Drug Market
-
Two departments issued a document to guidethe strengthening of drug cases investigation and handling
-
National Health Care Commission: 50% of thecountry's public hospitals above the second level have carried out appointmentdiagnosis and treatment services
-
India starts testing a pharmaceuticalcompany's exports of cough syrup
-
Inmanar Announces Several BreakthroughSequencing Innovations
-
China's medical supplies supply securitycapabilities continue to enhance
-
244 medical device concept stocks roseindustry insiders said the process of domestic replacement is expected toaccelerate
-
Rare diseases pose a challenge to thepharmaceutical industry
-
Pfizer's $11.6 Billion Double-acting Migraine Drug Generates $318 Million in First-half Revenue
Recommend Reading
-
Roche Keeps German Diagnostics Investment
-
India Raises Cancer Drug Price Caps by 50%
-
Pfizer Warns Germany Over Drug-Pricing Policy
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Ethylene Glycol Prices Recently Stop Declining—Beware of a Downward Spiral Triggered by a Sharp Drop in Crude Oil Prices
-
Cost Benefits Boost Polyester Staple Fiber Market to a Strong Start
-
Ethanol Market Prices Weakly Fluctuating
-
This Week China's Titanium Dioxide Market Rises (3.1-3.6)
-
Cost Benefits Support PTA Market’s “Strong Start”